NDA 217064 · Famygen Life Sci
Ryzumvi
Phentolamine Mesylate · Ophthalmic
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Sep 25, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
46
14 Phase 3, 7 recruiting
FAERS reports
139
91 serious, 11 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 9, 2026.
RYZUMVI is indicated for: • Treatment of presbyopia in adults. • Treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic agents (e.g., tropicamide) in adults and pediatric patients 3 years of age and older. RYZUMVI is an alpha-adrenergic blocker indicated for the: • treatment of presbyopia in adults. ( 1 ) • treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic agents (e.g., tropicamide) in adults and pediatric patients 3 years of age and older. ( 1 )
Mechanism: RYZUMVI is a relatively non-selective alpha-1 and alpha-2 adrenergic antagonist. Physiological dilation of the pupil is primarily controlled by the radial iris dilator muscles surrounding the pupil; these muscles are activated by the alpha-1 adrenergic receptors. Phentolamine reversibly binds to these receptors on the iris dilator muscle, thereby reducing pupil diameter, with no effect on the ciliary muscle. Phentolamine directly antagonizes the mydriatic effect of an α-1 adrenergic agonist, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 16, 2026 Supplement 5 · Efficacy LabelLetter
- Sep 25, 2023 Original approval · Type 3 - New Dosage Form LabelLetterReview
1 products under this application
- RYZUMVI · PHENTOLAMINE MESYLATE EQ 0.75% BASE · SOLUTION, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Phentolamine" as an intervention, any sponsor and status, largest first.
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual AcuityPivotal-lookingRecruiting
Opus Genetics, IncIndustry
NCT07140783 · 580 participants (planned) · Start Sep 2, 2025 · Primary completion Aug 2027
Drug: 0.75% Phentolamine Ophthalmic Solution; Placebo · For: Vision Loss Night; Vision Disorders
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 20 sites in all
- Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With PresbyopiaPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT06542497 · 569 participants · Start Aug 15, 2024 · Primary completion Apr 3, 2025
Drug: 0.75% phentolamine ophthalmic solution; Placebo · For: Presbyopia
Sites: Chandler, Arizona; Mesa, Arizona; Phoenix, Arizona · 39 sites in all
D. Walter WrayAcademic, hospital or other
NCT02966665 · 420 participants (planned) · Start Sep 2008 · Primary completion Aug 2030
Drug: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate; BQ-123 and 3 more · For: Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure and 1 more
Sites: Salt Lake City, Utah
- Intensive Blood Pressure Reduction in Acute Cerebral HaemorrhagePivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT00226096 · 404 participants · Start Nov 2005 · Primary completion Sep 2007
Drug: Labetalol Hydrochloride; Metoprolol tartrate and 9 more · For: CVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial Hemorrhages
Sites: Concord, Australia; Gosford, Australia; Kogarah, Australia · 20 sites in all
- Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)Pivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT05134974 · 368 participants · Start Nov 18, 2021 · Primary completion Mar 18, 2022
Drug: Phentolamine Ophthalmic Solution 0.75%; Phentolamine Ophthalmic Solution Vehicle · For: Mydriasis; Dilation
Sites: Newport Beach, California; Westminster, California; Delray Beach, Florida · 15 sites in all
- New Perspective on Exploring the Post-apneic BP Surge in Patients With OSAPivotal-lookingStatus unknown
Xu JAcademic, hospital or other
NCT06172998 · 350 participants (planned) · Start Apr 1, 2022 · Primary completion Apr 1, 2024
Drug: Phentolamine Injection · For: Obstructive Sleep Apnea
Sites: Huai'an, China
- Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With PresbyopiaPivotal-lookingCompleted
Opus Genetics, IncIndustry
NCT05646719 · 333 participants · Start Dec 22, 2022 · Primary completion Oct 11, 2023
Drug: Phentolamine Opthalmic Solution 0.75%; Low dose pilocarpine · For: Presbyopia
Sites: Phoenix, Arizona; Azusa, California; Newport Beach, California · 26 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ocular hyperaemia20
- blood urea increased14
- blood glucose increased13
- neutrophil count increased13
- anaemia12
- diarrhoea12
- headache12
- hypertension12
- lymphocyte count decreased12
- drug ineffective11
- dizziness10
- haemoglobin decreased10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2007 | 6 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 15 |
| 2012 | 5 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 15 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 20 |
| 2025 | 26 |
| 2026 | 12 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Erectile dysfunction.
Khera M, Goldstein I · BMJ Clin Evid 2011 · Systematic Review
- Phentolamine bioequivalence study.
Silva LF, Moraes MO, Santana GS, et al. · Int J Clin Pharmacol Ther 2004 · Clinical Trial, Comparative Study
- Erectile dysfunction: a global review of intracavernosal injectables.
Duncan C, Omran GJ, Teh J, et al. · World J Urol 2019 · Systematic Review
- [Chronic, refractory algodystrophy].
Zyluk A · Chir Narzadow Ruchu Ortop Pol 2006 · Clinical Trial, English Abstract
- Efficacy and Safety of Preemptive Magnesium Sulfate Infusion during Pheochromocytoma and Paraganglioma Resection: A Randomized, Double-blind, Placebo-controlled Trial.
Kong H, Zhang YX, Yin QL, et al. · Anesthesiology 2026 · Randomized Controlled Trial
- Acute Sympathetic Blockade Improves Insulin-Mediated Microvascular Blood Flow in the Forearm of Adult Human Subjects With Obesity.
Smith EC, Patel JN, Wahba A, et al. · J Am Heart Assoc 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Famygen Life Sci
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.